These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 27471647)

  • 1. Successful engineering of a highly potent single-chain variable-fragment (scFv) bispecific antibody to target disialoganglioside (GD2) positive tumors.
    Cheng M; Santich BH; Xu H; Ahmed M; Huse M; Cheung NK
    Oncoimmunology; 2016 Jun; 5(6):e1168557. PubMed ID: 27471647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retargeting T cells to GD2 pentasaccharide on human tumors using Bispecific humanized antibody.
    Xu H; Cheng M; Guo H; Chen Y; Huse M; Cheung NK
    Cancer Immunol Res; 2015 Mar; 3(3):266-77. PubMed ID: 25542634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potent antitumor effect of T cells armed with anti-GD2 bispecific antibody.
    Nakajima M; Guo HF; Hoseini SS; Suzuki M; Xu H; Cheung NV
    Pediatr Blood Cancer; 2021 Jul; 68(7):e28971. PubMed ID: 33844437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-chain Fv-streptavidin substantially improved therapeutic index in multistep targeting directed at disialoganglioside GD2.
    Cheung NK; Modak S; Lin Y; Guo H; Zanzonico P; Chung J; Zuo Y; Sanderson J; Wilbert S; Theodore LJ; Axworthy DB; Larson SM
    J Nucl Med; 2004 May; 45(5):867-77. PubMed ID: 15136638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural design of disialoganglioside GD2 and CD3-bispecific antibodies to redirect T cells for tumor therapy.
    Cheng M; Ahmed M; Xu H; Cheung NK
    Int J Cancer; 2015 Jan; 136(2):476-86. PubMed ID: 24895182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generation and characterization of a mouse single-chain antibody fragment specific for disialoganglioside (GD2).
    Moutel S; Birkle S; Laurence V; Michon J; Fridman WH; Aubry J; Teillaud JL
    Hybridoma; 1997 Aug; 16(4):335-46. PubMed ID: 9309424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alteration of Electrostatic Surface Potential Enhances Affinity and Tumor Killing Properties of Anti-ganglioside GD2 Monoclonal Antibody hu3F8.
    Zhao Q; Ahmed M; Guo HF; Cheung IY; Cheung NK
    J Biol Chem; 2015 May; 290(21):13017-27. PubMed ID: 25851904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chimeric single-chain variable fragment-human immunoglobulin G crystallizable fragment antibody against GD2 for neuroblastoma targeted immunotherapy.
    Laopajon W; Takheaw N; Kotemul K; Pata S; Hongeng S; Kasinrerk W
    Explor Target Antitumor Ther; 2023; 4(6):1145-1156. PubMed ID: 38213540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human derived dimerization tag enhances tumor killing potency of a T-cell engaging bispecific antibody.
    Ahmed M; Cheng M; Cheung IY; Cheung NK
    Oncoimmunology; 2015 Apr; 4(4):e989776. PubMed ID: 26137406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bispecific antibody does not induce T-cell death mediated by chimeric antigen receptor against disialoganglioside GD2.
    Hoseini SS; Dobrenkov K; Pankov D; Xu XL; Cheung NK
    Oncoimmunology; 2017; 6(6):e1320625. PubMed ID: 28680755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GD2-directed bispecific trifunctional antibody outperforms dinutuximab beta in a murine model for aggressive metastasized neuroblastoma.
    Zirngibl F; Ivasko SM; Grunewald L; Klaus A; Schwiebert S; Ruf P; Lindhofer H; Astrahantseff K; Andersch L; Schulte JH; Lode HN; Eggert A; Anders K; Hundsdoerfer P; Künkele A
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34285106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical evaluation of multistep targeting of diasialoganglioside GD2 using an IgG-scFv bispecific antibody with high affinity for GD2 and DOTA metal complex.
    Cheal SM; Xu H; Guo HF; Zanzonico PB; Larson SM; Cheung NK
    Mol Cancer Ther; 2014 Jul; 13(7):1803-12. PubMed ID: 24944121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy.
    Nazha B; Inal C; Owonikoko TK
    Front Oncol; 2020; 10():1000. PubMed ID: 32733795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel anti-GD2/4-1BB chimeric antigen receptor triggers neuroblastoma cell killing.
    Prapa M; Caldrer S; Spano C; Bestagno M; Golinelli G; Grisendi G; Petrachi T; Conte P; Horwitz EM; Campana D; Paolucci P; Dominici M
    Oncotarget; 2015 Sep; 6(28):24884-94. PubMed ID: 26298772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo.
    Cheung NK; Guo H; Hu J; Tassev DV; Cheung IY
    Oncoimmunology; 2012 Jul; 1(4):477-486. PubMed ID: 22754766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-Affinity GD2-Specific CAR T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model.
    Richman SA; Nunez-Cruz S; Moghimi B; Li LZ; Gershenson ZT; Mourelatos Z; Barrett DM; Grupp SA; Milone MC
    Cancer Immunol Res; 2018 Jan; 6(1):36-46. PubMed ID: 29180536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
    Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
    MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reducing epitope spread during affinity maturation of an anti-ganglioside GD2 antibody.
    Hu J; Huang X; Ling CC; Bundle DR; Cheung NK
    J Immunol; 2009 Nov; 183(9):5748-55. PubMed ID: 19812201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Minibody-Based and scFv-Based Antibody Fragment-Drug Conjugates Selectively Eliminate GD2-Positive Tumor Cells.
    Kalinovsky DV; Kholodenko IV; Kibardin AV; Doronin II; Svirshchevskaya EV; Ryazantsev DY; Konovalova MV; Rozov FN; Larin SS; Deyev SM; Kholodenko RV
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting GD2-Positive Tumor Cells by Pegylated scFv Fragment-Drug Conjugates Carrying Maytansinoids DM1 and DM4.
    Kalinovsky DV; Kholodenko IV; Svirshchevskaya EV; Kibardin AV; Ryazantsev DY; Rozov FN; Larin SS; Deyev SM; Kholodenko RV
    Curr Issues Mol Biol; 2023 Oct; 45(10):8112-8125. PubMed ID: 37886955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.